The article discusses a study which examined the efficacy and safety of long-term tofacitinib to treat alopecia areata. The study analyzed data from adult patients who received the drug for their alopecia areata. The patients reported adverse events such as hyperseborrhea, upper respiratory infections and acneiform eruptions.